Ann: Incannex to Acquire APIRx Pharmaceuticals, page-222

So regarding APIRx's gum patent(s), I'm guessing the 80% bioavailability aspect is very economically significant.
If the delivery of cannabinoids is 1.3 to 8 times more efficient than the two closest other delivery methods (tinctures and vaping), that's a lot less cannabinoids production required for the same result.

That has to be extremely appealing to the industry: it is the kind of raw cost reduction that finds itself at the forefront of priorities when optimising revenues. And it leaves a nice margin to keep their products clearly cheaper for the user than other CBD products.

It is also perhaps the least stigmatised way to ingest cannabinoids. A tincture is quite low profile too, but still more conspicuous.
Gum is just gum...

With CBDA and THCA proving to have some efficacy against Covid infection, gum would be a great way for folks who are not accustomed to any of the other ways of absorbing cannabinoids, to very simply reduce their risk of Covid infection. If they focus on this market, millions of people will then discover the other benefits of CBD and we could see the market expand a lot.

Not advice, do your own do.